Biochemical recurrence of prostate cancer: initial results with ¹⁸F-PSMA-1007 PET/CT

Biochemical recurrence (BCR) is a concern for prostate cancer patients after local treatment. ⁶⁸Ga-labeled prostate-specific membrane antigen (PSMA) ligands have significantly improved prostate cancer imaging. However, several ¹⁸F-labeled ligands that were developed as fluorinated tracers might present advantages. In this study, we analyzed the potential of ¹⁸F-PSMA-1007 in patients with BCR. Methods: Twelve patients with BCR after local treatment underwent PET/CT scans 1 and 3 h after injection of ¹⁸F-PSMA-1007. Results: ¹⁸F-PSMA-1007 PET/CT detected lesions in 9 of 12 patients (75%). A significant difference was observed when comparing the tracer uptake in ¹⁸F-PSMA-1007–positive lesions 1 and 3 h after injection (median SUV_max, 7.00 vs. 11.34; P < 0.001; n = 76). Fortyfour (88%) of 50 ¹⁸F-PSMA-1007–positive lymph nodes had a shortaxis diameter of less than 8 mm. Conclusion: In this pilot study, ¹⁸F-PSMA-1007 PET/CT presented high potential for localization of recurrent disease in prostate cancer patients with BCR.